Bayer Issues Earnings Nov. 25; Update Expected On Strategic Realignment
This article was originally published in The Pink Sheet Daily
Executive Summary
Company’s plans to expand its U.S. oncology business and its recent deal with Schering-Plough for primary care product marketing rights in the U.S. are likely to be a focus of discussion. Bayer’s shareholders approve spin-off of Lanxess chemicals/polymers unit.